The pharmaceutical industry is facing a period rich with opportunity and uncertainty as businesses are confronted by the need to generate growth in a mature, competitive market while faced with increasing pricing pressures and contracting margins.
Blockbuster patent expiries and the entry of biosimilar products has seen innovative pharmaceutical companies change direction, resulting in a blurring of traditional lines in the market. Coupled with unprecedented collaboration between global players, this is driving innovative approaches to commercialising IP and transformative asset-driven transactions.
Combining deep scientific and technical knowledge, we apply our commercial nous and experience to anticipate and deliver innovative, value-enhancing solutions.
We partner with our clients at every level of their businesses to help them achieve their goals: from strategic advice on "bet-the-company" transactions and disputes to merger control, regulatory investigations, commercial contracts and licensing.
Our intellectual property lawyers, the majority of whom have scientific or engineering backgrounds, understand that innovation is at the heart of the pharmaceutical industry. We help the world's leading pharmaceutical companies to use intellectual property to achieve commercial outcomes and competitive advantage, and have acted on some of the most complex transactions and disputes in the market.
Our integrated pharmaceuticals team spans our network of offices, and together with our preferred, trusted local law firms, work as one to provide commercial solutions—wherever you operate.
|
LIFE SCIENCES NOTES - Find analysis of the latest legal developments relevant to the life sciences.. |
Accolades
'Excellent patent litigation offering for biotech and pharmaceutical companies, best known for defending against generic challenges. Very strong on the interaction of IP law with competition and EU law. Also advises on IP licensing and freedom-to-operate exercises. Demonstrates expertise in UK and EU pharmaceutical regulations.'
Life Sciences: Patent Litigation, Chambers UK, 2020
"They are exceptional and I wouldn't hesitate to recommend them. They are very personable, they got to understand our business quickly and the service was first class." (Client quote)
Life Sciences: Patent Litigation, Chambers UK, 2020
'The team is highly recommended for their IP and regulatory skills, combining advice and litigation capabilities.'
Life Sciences & Healthcare, Legal 500 Italy
"We enjoy their worldwide presence and use them in Australia and other jurisdictions; they are able to co-ordinate big, worldwide legal battles and it's good to have a network of lawyers working together for a common goal." (Client quote)
Life Sciences, Chambers Asia-Pacific: Australia 2020
‘A top-tier team, very impressive.’ (Client quote)
Pharmaceuticals & Biotechnology, Legal 500 UK 2020
"our go-to firm in Australia – there's no need to look elsewhere." Another reports: "They are the only firm that has the capacity to advise across the board for all areas of our business, which is why we keep using them. They do the stuff that requires hard thinking. ." (Client quote)
Life Sciences, Chambers Asia-Pacific: Australia 2020
‘The lawyers combine the high quality and sophisticated knowledge of a boutique law firm with the approach, mind-set and language skills of an international firm. So what we get is a combination of high-quality legal advice given to us in a very concise, practical and helpful way.' (Client quote)
Life Sciences & Healthcare, Legal 500 Italy
Rankings
Tier 1, Pharmaceuticals & Biotechnology
Legal 500 UK 2020
Band 1, Life Sciences
Chambers Australia 2020
Tier 3, Life Sciences & Healthcare
Legal 500 Italy 2020
Team Awards
Firm of the Year: Patent Strategy & Management
LMG European Life Sciences Awards 2020
Firm to Watch: Litigation & Enforcement
LMG European Life Sciences Awards 2020
Life Sciences Firm of the Year – Italy
LMG European Life Sciences Awards 2020
Recent Experience
Indivior plc
in connection with the Relationship Agreement and settlement reached with the Company’s largest shareholder, the activist investor Scopia Management
Parkinson's UK
on its acquisition of assets relating to the research, development, manufacture and marketing of glial-cell line-derived neurotrophic factor (GDNF), a potentially disease-modifying treatment for Parkinson's disease
SK Holdings
on its acquisition of Yposkesi, a French market leader in gene therapy and viral vector manufacturing
Acacia Research Corporation
on its entry into an agreement with Link Fund Solutions Limited to purchase shares in up to 19 public and private life sciences companies from the LF Equity Income Fund for up to £223.9 million.
FederFARMACO
a company representing pharmaceutical wholesalers, on regulatory affairs and intellectual property matters
Mirnagreen
in relation to the launch and correct classification of new products based on a disruptive technology for extracting microRNA from plants, including advising on strategy to mitigate risks related to a misclassification under the contiguous categories of medicinal products, novel food and food supplements
Insights and updates
